Preview

Rational Pharmacotherapy in Cardiology

Advanced search

EXPERIENCE OF RAMIPRIL (HARTIL) USAGE IN PATIENTS WITH HIGH CARDIOVASCULAR RISK (THE OPTIMIST STUDY)

https://doi.org/10.20996/1819-6446-2009-5-6-13-18

Full Text:

Abstract

Aim. To evaluate efficacy and safety of ramipril (Hartil, Egis) in treatment of patients with different cardiovascular risk (according to arterial hypertension (HT) risk stratification) in real clinical practice.

Material and methods. 998 patients (424 men and 574 women; aged 57,4±0,4 y.o.) with HT; with combination of HT and ischemic heart disease; with ischemic heart disease and high normal blood pressure (BP) were included in the open non-control non-comparative multicenter phase IV study. The anamnesis data collection, physical examination, evaluation of risk factors, the target organ damage, the associated cardiovascular diseases, total cardiovascular risk, previous therapy, and also BP measurement were performed. All patients received ramipril within 8 weeks additionally to previous antihypertensive therapy. The BP measurement was performed initially, after 4 and 8 weeks of therapy. Achievement of target BP level (BP<140/90 or <130/80 mm Hg in patients of high or very high cardiovascular risk) was used as efficacy criterion.

Results. 790 (82,1%) hypertensive patients used antihypertensive therapy before the study. 675 (85,4%) patients received ACE inhibitors, 435 (55%) patients - beta-blockers, 230 (29,1%) patients - calcium channel blockers, 420 (53,2%) patients – diuretics and 28 (3,5%) patients - angiotensin II receptor blockers. Ramipril additionally to previous therapy provided achievement of target BP in 69,4% of patients with high and in 64,8% of patients with very high cardiovascular risk.

Conclusion. Addition of a ramipril to the treatment of patients with high and very high cardiovascular risk increases efficacy of the therapy.

About the Authors

I. A. Velizhanina
Tyumen Cardiology Center, Affiliate of Research Institute for Cardiology of Siberian Branch of Russian Academy of Medical Sciences
Russian Federation
Melnikaite ul. 111, Tyumen, 625026


L. I. Gapon
Tyumen Cardiology Center, Affiliate of Research Institute for Cardiology of Siberian Branch of Russian Academy of Medical Sciences
Russian Federation
Melnikaite ul. 111, Tyumen, 625026


E. S. Velizhanina
Tyumen Cardiology Center, Affiliate of Research Institute for Cardiology of Siberian Branch of Russian Academy of Medical Sciences
Russian Federation
Melnikaite ul. 111, Tyumen, 625026


M. I. Shupina
Omsk State Medical Academy of Federal Agency for Health Care and Social Development
Russian Federation
Lenina ul. 12, Omsk, 644043


A. V. Rudakov
Tyumen Cardiology Center, Affiliate of Research Institute for Cardiology of Siberian Branch of Russian Academy of Medical Sciences
Russian Federation
Melnikaite ul. 111, Tyumen, 625026


T. S. Bondarenko
Tyumen Cardiology Center, Affiliate of Research Institute for Cardiology of Siberian Branch of Russian Academy of Medical Sciences
Russian Federation
Melnikaite ul. 111, Tyumen, 625026


References

1. Диагностика и лечение артериальной гипертензии. В: Оганов Р.Г., Мамедов М.Н., редакторы. Национальные клинические рекомендации. М.: Меди ЭКСПО; 2009. С.5-34.

2. Диагностика и лечение стабильной стенокардии. В кн. Оганов Р.Г., Мамедов М.Н., редакторы. Национальные клинические рекомендации. М.: Меди ЭКСПО; 2009. С.35-73.

3. Mancia G., De Backer G., Dominiczak A., et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management ofArterialHypertension ofthe European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105-87.

4. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, при- ем антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Российский кардиологический журнал 2006;(4):45-50.

5. Wright J.T. Jr., Bakris G., Greene T. et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease:results from theAASK trial.JAMA2002; 288(19):2421- 31.

6. Kaplan N.M. The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin Ther 1996;18(4):658-70.

7. Agabiti-Rosei E., Ambrosioni E., Dal Palù C. et al. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results ofthe RACE (ramipril cardioprotective eval￾uation) study on behalf of the RACE study group. J Hypertens 1995;13(11):1325-34.

8. Колос И.П., Мартынюк Т.В., Сафарян А.С. и др. Изучение эффективности терапии ингибитором ангиотензинпревращающего фер- мента рамиприлом и его комбинации с гидрохлортиазидом у пациентов с артериальной гипертонией и избыточной массой тела: исследование ХАРИЗМА. Кардиоваскулярная терапия и профилактика 2008;7(2):65-71.

9. Lüders S., Schrader J., Berger J. et al. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitorramipril in patients with high-normal blood pressure: a prospective,randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26(7):1487-96.

10. Yusuf S., Sleight P., Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor,ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342(3):145-53.

11. Диагностика и лечение хронической сердечной недостаточности. В: Оганов Р.Г., Мамедов М.Н., редакторы. Национальные клинические рекомендации. М.: Меди ЭКСПО; 2009. С. 97-164.

12. Кобалава Ж.Д., Котовская Ю.В. Антигипертензивная терапия и ишемическая болезнь сердца: клиническое значение исследования CAMELOT. Сердце 2005;4(5):287-93.

13. Карпов Ю.А., Деев А.Д. Российские клинические исследования: КАРДИНАЛКАРДилопин: эффективность и качество жизни при артериальной гипертензии. Кардиология 2008;(10):13-8.

14. Леонова М.В., Белоусов Д.Ю., аналитическая группа исследованияПИФАГОР.Первое российское фармакоэпидемиологическое исследование артериальнойгипертонии.Качественная клиническая практика 2002;(3):47–53.

15. Европейские рекомендации по профилактике сердечно-сосудистых заболеваний в клинической практике. Рациональная фармакотерапия в кардиологии 2008;3(приложение):4-40.


For citation:


Velizhanina I.A., Gapon L.I., Velizhanina E.S., Shupina M.I., Rudakov A.V., Bondarenko T.S. EXPERIENCE OF RAMIPRIL (HARTIL) USAGE IN PATIENTS WITH HIGH CARDIOVASCULAR RISK (THE OPTIMIST STUDY). Rational Pharmacotherapy in Cardiology. 2009;5(6):13-18. (In Russ.) https://doi.org/10.20996/1819-6446-2009-5-6-13-18

Views: 415


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)